MétaCan
Menu
Back to cohort
Record W4415438746 · doi:10.51731/cjht.2025.1261

Nivolumab Plus Ipilimumab (Opdivo Plus Yervoy)

2025· article· W4415438746 on OpenAlexaboutno aff
CDA-AMC

Bibliographic record

VenueCanadian Journal of Health Technologies · 2025
Typearticle
Language
FieldMedicine
TopicCancer Immunotherapy and Biomarkers
Canadian institutionsnot available
Fundersnot available
KeywordsIpilimumabNivolumabColorectal cancerMicrosatellite instabilityDrugMetastatic melanomaSystemic therapyDisease

Abstract

fetched live from OpenAlex

Canada’s Drug Agency (CDA-AMC) recommends that Opdivo in combination with Yervoy be reimbursed by public drug plans for the first-line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer, if certain conditions are met. Opdivo in combination with Yervoy should only be covered to treat adult patients with histologically confirmed, locally advanced, unresectable or metastatic colorectal cancer (mCRC)that has not previously been treated with systemic therapy for advanced disease and is not amenable to surgery and that has a known tumour MSI-H or dMMR status based on validated test(s) per local standard of practice. Opdivo in combination with Yervoy should only be reimbursed if prescribed by clinicians with expertise in the diagnosis and treatment of patients with mCRC and if the cost of Opdivo in combination with Yervoy is reduced.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: none
Teacher disagreement score0.007
Threshold uncertainty score0.024

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0070.003

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.025
GPT teacher head0.303
Teacher spread0.278 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueCanadian Journal of Health TechnologiesSame topicCancer Immunotherapy and BiomarkersFrench-language works237,207